- Company
- Chong Kun Dang signs KRW 1.7 tril deal with Novartis
- by Kim, Jin-Gu Nov 7, 2023 05:34am
- On the 6th, Chong Kun Dang Pharm announced on the 6th that it signed a licensing out agreement worth KRW 1.7 trillion for its new drug candidate 'CKD-510' with the global pharmaceutical company Novartis. Under the agreement, Novartis will have exclusive rights to the development and commercialization of CKD Pharm’s CKD-510 worldwide, ex
- Company
- First GIFT drug Lunsumio in reimb process after approval
- by Eo, Yun-Ho Nov 7, 2023 05:33am
- The new lymphoma drug ‘Lunsumio' started the insurance reimbursement process immediately after its approval in Korea. According to industry sources, the anti-CD20/CD3 T-cell engaging bispecific antibody Lunsumio (mosunetuzumab) is starting the listing process using the approval-reimbursement evaluation linkage system. Lunsumio is the
- Company
- Scemblix may be prescribed at Big 5 Hospitals in KOR
- by Eo, Yun-Ho Nov 6, 2023 05:27am
- The next-generation chronic myeloid leukemia drug ‘Scemblix’ can now be prescribed at general hospitals in Korea. According to the industry sources, Novartis Korea's Philadelphia chromosome-positive chronic myeloid leukemia (Ph+CML) treatment ‘Scemblix (asciminib)' has passed the drug committees of the Big 5 tertiary hospitals in Korea
- Company
- Wegovy and Mounjaro begin to dominate the obesity market
- by Kim, Jin-Gu Nov 6, 2023 05:27am
- Novo Nordisk Wegovy and Eli Lilly Mounjaro have grown explosively in the global market. The two products together generated sales of close to 4 trillion won by the third quarter. In the future, if Mounjaro officially obtains an obesity treatment indication from the FDA, competition between the two products is expected to become more intense.
- Company
- Polivy’s reimb soon to receive CDDC review
- by Eo, Yun-Ho Nov 6, 2023 05:26am
- Whether progress will be made for the reimbursement of the lymphoma treatment ‘Polivy,’ which has applied for reimbursement again after changing its indication to the first-line, is gaining attention. According to industry sources, schedule coordination is underway for the review of the agenda of reimbursing Roche Korea’s Diffuse Large
- Company
- Expansion of coverage for SMA treatment Spinraza
- by Nov 3, 2023 05:32am
- Differentiation between single-dose Zolgensma and oral Evrysdi “Spinraza welcomes relaxation of salary standards” Hyeongjun Park, Professor of Neurology at Gangnam Severance Hospital, gave a presentation on changes in the SMA treatment environment. Biogen's Spinraza, a treatment for spinal muscular atrophy (SMA) with the advantage of dir
- Company
- Cosentyx is approved for hidradenitis suppurativa
- by Eo, Yun-Ho Nov 3, 2023 05:32am
- 'Cosentyx' has entered the field for hidradenitis suppurativa where no other treatment option than ‘Humira’ had been available until now. Moreover, the company plans to immediately enter the market for the indication in Korea as well. According to industry sources, Novartis Korea recently submitted an application to the Ministry of
- Company
- Novartis Jakabi expands graft-versus-host disease coverage
- by Nov 2, 2023 05:35am
- Novartis Korea announced that Jakabi, a Janus Kinase (JAK) inhibitor, will be covered by insurance for the treatment of acute or chronic graft-versus-host disease from November 1. About 1 year and 6 months after Jakabi was approved for graft-versus-host disease indication in May of last year, insurance benefits were applied to patients aged
- Company
- Reblozyl can be prescribed in general hospitals in KOR
- by Eo, Yun-Ho Nov 2, 2023 05:35am
- Reblozyl, a treatment for myelodysplastic syndrome, can now be prescribed in general hospitals in Korea. According to industry sources, BMS Korea’s Reblozyl (luspatercept-aamt) passed the drug committees (DCs) of several medical institutions in Korea including Samsung Medical Center and Sinchon Severance Hospital. Reblozyl is indicat
- Company
- Public petition filed for the reimb of Verzenio
- by Eo, Yun-Ho Nov 2, 2023 05:35am
- A public petition imploring the government to reimburse Verzenio for early breast cancer has been posted online for review. On October 31st, a petition was posted on Cheong Wa Dae’s National Petition Bulletin Board entitled ‘Petition requesting reimbursement for Verzenio (abemaciclip), a targeted treatment for early breast cancer
